We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
In 2021, the FDA’s Center for Drug Evaluation and Research (CDER) issued fewer warning letters but conducted moregood clinical practice inspections that the previous year, according to the annual report from CDER’s Office of Compliance (OCC). Read More
The approval was supported by positive data from two pivotal studies in which patients showed significant improvement in the disease over those who received a placebo. Read More
The FDA has released four related final guidances to help drugmakers submit electronic safety reports — including advice on how to conform to the latest International Council for Harmonization (ICH) standard. Read More
The FDA issued a Form 483 with nine observations to generics manufacturer Aurolife Pharma following a six-week inspection of the company’s manufacturing facility in Dayton, N.J., from Oct. 25 through Dec. 7, in which the company attributed some of its data deficiencies to a cyberattack. Read More
SK Bioscience said it also plans to submit emergency use applications to the World Health Organization and to regulatory agencies around the world. Read More
The European Commission has approved Merck’s blockbuster oncology drug Keytruda (pembrolizumab) for six new indications, including persistent, recurrent or metastatic cervical cancer. Read More